




At a Glance

Meet an independently-owned developer and manufacturer of Finished Dosage Forms (FDF) and Active Pharmaceutical Ingredients (API).

From its headquarters in Barcelona, Spain, Medichem has grown into **one of the largest worldwide manufacturers of Generics and Chlorhexidine in the pharmaceutical industry**.

Over the years, Medichem has been **at the forefront of innovation** and as such has developed 80 value-added and high-quality drug products.





People First

OUR GREATEST ASSET


Without the commitment of our 450 employees around the world, Medichem wouldn't be one of the worldwide leading manufacturers in the pharmaceutical industry.

Empowering team members to deliver results at this level requires ongoing investment in our workforce, from recruiting to training to quality-of-life considerations. This is how Medichem supports team members to go above and beyond in their daily work.

ADE WITH CARE

A SIMPLE PLEDGE

Medichem team members have many different backgrounds and talents, yet we share the same perspective: that quality comes first and special care needs to be given to every step of development and manufacturing and during each customer interaction.



Added-Value Generics



Medichem develops and manufactures cGMP Active Pharmaceutical Ingredients (API), including Highly Potent APIs (HPAPI) and Finished Dosage Forms (FDF).

Over the past few years, Medichem has focused on APIs and FDFs with particular technological barriers, creating 70 value-added products aimed at various therapeutic areas.

FINISHED DOSAGE FORMS

More recently, Medichem has turned the spotlight on FDF, focusing on innovative formulations of injectables and solid oral drugs.



SOLID ORAL DOSAGE

- Capsules
- Tablets
- Film-coated tablets
- · Pellets-filled sprinkle caspules



ORAL SOLUTIONS

Oral Solution in bottle



STERILE FORMS

- · Ampoule blow-fill-seal
- Powder for solution for injection or infusion
- · Pre-filled syringe
- · Solution for injection, inhalation and infusion







Chlorhexidine & other antiseptics

Medichem started manufacturing chlorhexidine salts back in 1985. Since then, we have become one of the world's largest manufacturers while enlarging our portfolio and expanding into new markets.







Despite the numerous applications for chlorhexidine, we manufacture it using the same quality system we apply to Active Pharmaceutical Ingredients.



Medichem CDG* is listed under article 95 of the EU Biocidal Products Regulation (BPR).



Successful FDA inspections of our Spanish site since 1999.



First manufacturer to obtain the CEP back in 1998.



Collaboration in the development of the CDG* monograph.

Innovation and Excellence

R&D is the root of Medichem's strategy and success. Highly-qualified personnel engage daily in technically challenging projects, with the objective of developing high-quality value-added drug products. Medichem has extensive and proven know-how in solid and injectable dosage forms; moreover, we have HPAPI capabilities that enable us to develop breakthrough products.

From the very first step, every development program is designed to meet all regulatory requirements, to the highest standard of quality, with set goals and achievement monitoring.

WORLDWIDE DEVELOPMENTS

SPAIN -

Celrà and Barcelona API and FDF

MALTA ·

Hal Far

API, FDF and HPAPI

12%

Company turnover dedicated to R&D

UNIQUE

High-value products, combined with new technology platforms



Meeting all the regulatory requirements, to the highest EU and US standards of quality

USA

Several new 505(b)(2) opportunities in progress





Manufacturing to the highest standards

When managing multi-purpose production lines, our primary goal is to maintain a safe workplace for our team to be able to manufacture to the highest quality standards of the pharmaceutical industry, while ensuring a timely delivery to our clients.

VERTICALLY-INTEGRATED: FROM INTERMEDIATES TO FDF



STATE-OF-THE-ART TECHNOLOGIES

API

- Flow chemistry
- Nanofiltration
- Chromatographic purification Ø200 mm
- Hydrogenation Biazzi®, 10 bar

FDF

- Wet and dry granulation
- Roller compaction
- Coating
- Capsule filling
- Blistering and bottling

HPAPI


 OEL (Occupation Exposure Limit) down to 40 ng/m³



Successful Partnerships

Medichem has developed a solid base of international clients and delivers products to more than 70 countries, including the United States and within Europe, while consolidating alliances with strategic partners.

To better answer our global growth and customer requests, last year Medichem opened an **office in the USA** in addition to our **headquarters in Barcelona**, Spain, and our **commercial office in China**.



Read our customer and partner stories online: www.medichem.es

Regulatory Affairs

Requests for **scientific data that supports the quality, safety and efficacy of drugs** from Regulatory Authorities all over the world are addressed on a daily basis by Medichem's regulatory team. These key staff members have long-standing expertise dealing with diverse requirement-based scenarios across the world, with a focus on Europe and the USA.

In our team you will find **personalized, agile support** to ensure access to any market in a rapid manner, supported by reliable, scientifically-driven documentation. We provide the best possible grounds for success regardless of how hard to reach it may seem. Nothing is out of reach for us.

LONG-STANDING EXPERTISE

877

MARKETING AUTHORIZATIONS

339

DMFS

15

CERTIFICATES OF SUITABILITY

...submitted to date to Regulatory Agencies around the globe





Be first-to-market

INTELLECTUAL PROPERTY is a key strategic asset at Medichem, which fully supports and protects the business interests of its clients. Thanks to its two strategic facilities in Malta, Medichem can provide clients with first-to-market opportunities due to Malta's unique patent situation, which will **continue to be advantageous and offer smart opportunities when the SPC manufacturing waiver becomes applicable in July 2022.**


Products are selected with an advantageous patent strategy, ensuring the freedom to operate and at the same time protecting Medichem's innovative ideas with a global patent portfolio. Medichem's experienced IP team employs multiple IP approaches creating both long- and short-term competitive advantages.



Contract Services

Medichem offers a wide range of contract services, whether that be the manufacturing of APIs (including HPAPI) or the manufacturing and packaging of the finished dosage form, testing or release services.

TAILOR-MADE SOLUTIONS



The strategic planning and location in Malta of Medichem and Combino Pharm allow the launch of new products to the market, from the first day after the expiration date of the patent. Being the first to launch is without a doubt key to achieving optimal market penetration.





Reliability, a company value built over half a century

Medichem consolidated its business model between 1972 and 1985. During this time, a generic company earned the first "Paragraph IV" patent certification from the US regulatory agency, the FDA, using the API produced by Medichem. This paved the way for Medichem's market expansion in the USA and globally.







THE FOUNDING OF MEDICHEM

1985-2004



US MARKET ENTRY

• The first **FDA** audit, API - Spain - 1985

2005-12



EU EXPANSION

Start of Malta facilities

- The first EU GMP certification: API 2007, FDF 2006
- The first FDA audit: API 2007
- FDF licensing-out in Europe
- . Start of the HPAPI unit in Malta

The first EU GMP Certification, Spain - 2008

2009-14



ASIAN EXPANSION

- The first Japanese **PMDA** inspections. Spain 2009
- The founding of the **R&D** center in Nanjing, China
- Joint Venture **API intermediates** plant, China
- The first Korean FDA (MFDS) inspection, Spain 2012

2015-16



SPANISH ENTITIES CONSOLIDATION

• Medichem and Combino Pharm merge

2016-19



US EXPANSION AND ESTABLISHMENT

- The first FDA audit: FDF 2017
- . Opening of the US Office
- One ANDA approved
- Two ANDAs submitted
- . Two ANDAs submitted as CMO



WORLDWIDE EXPERTISE AND RELIABILITY

· Final client distribution

43% Europe 39% North America 18% ROW



MEDICHEM S.A.

Carrer de Fructuós Gelabert, 6 08970 Sant Joan Despí, Barcelona - SPAIN Tel: +34 93 477 64 40

MEDICHEM USA, LLC

Hoboken Business Center 50 Harrison Street, Suite 217 Hoboken, NJ 07030 - USA Tel: +1 201 420 1800

MEDICHEM, NRC

No.1698 Shuanglong Avenue Room 702 Kinefine Center Nanjing - PRC Tel: +86-18602518443

MEDICHEM MANUFACTURING (MALTA) LTD.

Hal Far (BBG) MALTA

MEDICHEM, S.A. - MANUFACTURING

Celrà (Girona) SPAIN

COMBINO PHARM (MALTA) LTD.

Hal Far (BBG) MALTA

www.medichem.es

info@medichem.es

October 201

This brochure is for informative purposes only. Even though Medichem has used good faith efforts to provide accurate and complete information, Medichem makes no warranties or representation of any kind, whether express or implied, as to the nature, accuracy, completeness of any information provided herein, or non-infringement of intellectual property rights, merchantability and/or fitness for a particular use of Medichem's products and Medichem does not assume any liability resulting thereof.